Cost-Effectiveness Analysis of Interventional Liver-Directed Therapies for a Single, Small Hepatocellular Carcinoma in Liver Transplant Candidates

被引:3
|
作者
Wu, Xiao [1 ]
Heller, Michael [1 ]
Kwong, Allison [3 ]
Fidelman, Nicholas [1 ]
Mehta, Neil [2 ]
机构
[1] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Gen Hepatol & Liver Transplantat, 513 Parnassus Ave,Room S-357, San Francisco, CA 94143 USA
[3] Stanford Univ, Dept Gastroenterol & Hepatol, San Francisco, CA USA
关键词
TRANSARTERIAL CHEMOEMBOLIZATION; RADIOFREQUENCY ABLATION; TRENDS; RESECTION; OUTCOMES; SCORE; Y-90;
D O I
10.1016/j.jvir.2023.02.016
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To assess the cost effectiveness of 3 main locoregional therapies (LRTs) (transarterial chemoembolization [TACE], transarterial radioembolization [TARE], and percutaneous ablation) as bridging therapy.Materials and Methods: A cost-effectiveness analysis was performed comparing the 3 LRTs for patients with a single hepatocellular carcinoma (HCC) with a diameter of 3 cm or less over a 5-year time horizon from a payer's perspective. The clinical courses, including transplantation, decompensation resulting in delisting, and the need for a second LRT, were based on data from the United Network for Organ Sharing (2016-2019). Costs and effectiveness were measured in U.S. dollars and quality-adjusted life-years, respectively. Probabilistic and deterministic sensitivity analyses were performed. Results: A total of 2,594, 1,576, and 903 patients underwent TACE, ablation, and TARE, respectively. Ablation was the dominant strategy, with the lowest expected cost and highest effectiveness. The probabilistic sensitivity analysis demon-strated that ablation was the most cost-effective strategy in 93.9% of simulations. A subgroup analysis was performed for different wait times, with ablation remaining the most cost-effective strategy. The sensitivity analysis showed that ablation was most effective if the risk of waitlist dropout was less than 2.00% and the rate of transplantation was more than 15.1% quarterly. TARE was most effective if the risk of dropout was less than 1.19% and the rate of transplantation was more than 24.0%. TACE was most effective if the risk of dropout was less than 1.01% and the rate of transplantation was more than 45.7%. Ablation remained the most cost-effective modality until its procedural cost was more than $34,843.Conclusions: Ablation is the most cost-effective bridging strategy for patients with a single, small (& LE;3 cm) HCC prior to liver transplantation. The conclusion remained robust in multiple sensitivity analyses.
引用
收藏
页码:1237 / 1246.e3
页数:13
相关论文
共 50 条
  • [31] Cost-effectiveness analysis of screening techniques for the detection of portal vein thrombosis and hepatocellular carcinoma in pre-liver transplant patients.
    Barghout, VE
    Biddle, AK
    Zacks, SL
    HEPATOLOGY, 1999, 30 (04) : 484A - 484A
  • [32] Localized hepatocellular carcinoma: Is liver-directed therapy alone as efficacious as surgical resection?
    Geranios, Karina C.
    Littau, Michael J.
    Park, Simon S.
    Baker, Talia B.
    Gilcrease, G. Weldon
    Cizman, Ziga
    Smith, Tyler
    Baker, Marshall S.
    SURGERY, 2025, 179
  • [33] Myeloid Cell Populations in Patients With Hepatocellular Carcinoma: Correlation With Liver-directed Therapy
    Newell, Pippa
    Savage, Talicia
    Cottam, Ben
    Wolf, Ron
    Hammill, Chet
    Sasadeusz, Kevin
    Thiesing, Tyler
    Crittenden, Marka
    Hansen, Paul
    Gough, Michael
    JOURNAL OF IMMUNOTHERAPY, 2012, 35 (09) : 758 - 758
  • [34] Cost-Effectiveness of HCV Treatment Among Liver Transplantation Candidates
    Cholapranee, Aurada
    Leff, Jared A.
    Kinkhabwala, Milan
    Litwin, Alain H.
    Schwartz, Jonathan M.
    Linas, Benjamin P.
    HEPATOLOGY, 2016, 64 : 54A - 55A
  • [35] Optimal Imaging Surveillance Schedules after Liver-Directed Therapy for Hepatocellular Carcinoma
    Boas, F. Edward
    Do, Bao
    Louie, John D.
    Kothary, Nishita
    Hwang, Gloria L.
    Kuo, William T.
    Hovsepian, David M.
    Kantrowitz, Mark
    Sze, Daniel Y.
    JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2015, 26 (01) : 69 - 73
  • [36] Impact of Low Muscle Mass on Hepatocellular Carcinoma Patients Undergoing Transcatheter Liver-Directed Therapies: Systematic Review & Meta-Analysis
    Chen, Yen-Chun
    Kuo, Meng-Hsuan
    Hsu, Ching-Sheng
    Kao, I-Ting
    Wu, Chen-Yi
    Tseng, Chih-Wei
    Shao, Shih-Chieh
    CANCERS, 2024, 16 (02)
  • [37] Cost-Effectiveness Analysis of Liver Resection Versus Transplantation for Early Hepatocellular Carcinoma Within the Milan Criteria
    Lim, Kheng Choon
    Wang, Vivian W.
    Siddiqui, Fahad J.
    Shi, Luming
    Chan, Edwin S. Y.
    Oh, Hong Choon
    Tan, Say Beng
    Chow, Pierce K. H.
    HEPATOLOGY, 2015, 61 (01) : 227 - 237
  • [38] Liver-Directed Combined Radiation Therapy for Downstaging Beyond-Milan Hepatocellular Carcinoma to Liver Transplantation
    Kim, Jina
    Kim, Yong Tae
    Lee, Jae Geun
    Han, Dai Hoon
    Joo, Dong Jin
    Kim, Do Young
    Seong, Jinsil
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 119 (04): : 1171 - 1178
  • [39] Comparison of Locoregional Therapies for Hepatocellular Carcinoma in Liver Transplant Recipients
    Chen, M.
    Philosophe, B.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 : 436 - 436
  • [40] Impact of hepatic function and tumor extent on survival in patients with unresectable hepatocellular carcinoma treated with liver-directed therapies.
    Hill, Marisa E.
    Basu, Sanjib
    Arslan, Bulent
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)